erial No FORM PTO 1449 (modified Atty. Docket No. 09/647,278 X-11965 INFORMATION DISCLOSURE CITEMION Applicants IN AN APPLICATION MAY 1 6 2001 MAY 1 8 2001 Janet M. Hock Group Filing Date TECH CENTER 1600/290(1654 1646 9/26/2000 U.S. PATENT DOCUMENTS Class Sub-Filing Date Document Number Date Name Examiner II class **Initial** Appropriate 4,086,196 4/25/78 Tregear AA RLi 4,698,328 10/6/87 Neer et al. AB RLI AC AD FOREIGN PATENT DOCUMENTS Sub-Translation Class Document Number Date Country class no yes 09.04.98 WO BA 98/14478 RLi 99/12561 18.03.99 WO RLi 19.03.96 BC 08073376 RLi OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Hirano T, et al., "Anabolic Effects of Human Biosynthetic Parathyroid CA Hormone Fragment (1034), LY333334, on Remodeling and Mechanical RLi Properties of Cortical Bone in Rabbits," Journal of Bone and Mineral Research, Vol. 14, No.4, 536-545 (1999). Lindsay, R. et al., "Randomised controlled study of effect of СВ parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis, " The Lancet, Vol. 350, 550-555 (1997). Macgill, K. et al., "Vascular Effects of PTHrP (1-34) and PTH (1-34) in \overline{CC} the Human Fetal-Placental Circulation, "Placenta, Vol. 18, 587-592 (1997).Lindsay, R. et al., "Subcutaneous Administration of the Amino-Terminal CD Fragment of Human Parathyroid Hormone- (1-34): Kinetics and Biochemical Response in Estrogenized Osteoporotic Patents, " Journal of Clinical Endocrinology and Metabolism, Vol. 77, No. 6, 1535-1539 Lane, N. et al., "Parathyroid Hormone Treatment Can Reverse CE Corticosteroid-Induced Osteoporosis, " J. Clin. Invest., Vol. 102, No. 8, 1627-1633 (October 1998). Cosman F. et al., "Is Parathyroid Hormone a Therapeutic Option for CF Osteoporosis? A Review of the Clinical Evidence, " Calcified Tissue International, Vol. 62, 475-480 (1998). Hesch, R.D. et al., "Results of a Stimulatory Therapy of Low Bone CG Metabolism in Osteoporosis with (1-38)hPTH and Diphosphonate EHDP, " Klinische Wochen Schrift, Vol. 66, 976-984 (1988). Cosman, F., et al, "Estrogen Protection against Bone Resorbing Effects CH of Parathyroid Hormone Infusion, " Annals of Internal Medicine, Vol. 118, No. 5, 337-343 (1993) DATE CONSIDERED EXAMINER Ruishang L. 7/29/2002 *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy

ヒノ

of this form with next communication to the applicant.

TORM PTO 1449	odified)					
	RADEMAN	Atty. Docket No. X-11965	Serial No 09/647,278			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Janet M. Hock				
		Filing Date 9/26/2000	Group 1654 1646			
CI	Increase the Mechania	cal Strength and Thicks	rmone (1034) and (1084) ness of Cortical Bone in			
RLi	Rats," " Journal of .	Bone and Mineral Resear	rch, Vol. 3, No. 9, 1097-1101			
CJ	Parathyroid Hormone	1-34 Peptide in Ovaried	For 3 Months With Human ctomized Cynomolgus Monkeys 4, Supplement, 415S-420S			
	(1995)					
СК	Dempster D.W., et al Bone, " Endocrine Rev	., "Anabolic Actions of iews, Vol. 14, No. 6, (f Parathyroid Hormone on 690-709, (1993).			
CL	Fujita, T., et al., Parathyroid Hormone Prospective Study Us	"Effect of an Intermit (1-34) on Osteoporosis ing Three Dose Levels, 9).	tent Weekly Dose of Human : A Randomized Double-Masked " Osteoporosis International,			
CM	Hesch, R.D. et al., Therapy with Pulsati Nasal Spray in Osteo	"Increase of Vertebral le 1-38hPTH and Sequent porotic Patients," Cal-	Density by Combination tial Addition of Calcitonin cified Tissue International,			
CN	Hodsman, A.B. et al. Efficacy of Cyclical Hormone and Sequenti Women with Osteoporo	, "A Randomized Control Parathyroid Hormone Vo al Calcitonin to Impro- sis," Journal of Clini No. 2. 620-628, (1997).			
со	Reeve, J. et al., "A on Trabecular Bone i British Medical Jour	nabolic Effect of Human n Involutional Osteopo nal, Vol. 280, 1340-13	n Parathyroid Hormone Fragment rosis: A Multicentre Trial," 44, (1980).			
СР	Hesp, R. et al., "Th Density and Calcium Treated with Human P	e Relationship between Balance in Patients wi	Changes in Femoral Bone th Involutional Osteoporosis gment (hPTH 1034), " Metabolic			
CQ	Reeve, J. et al., "h Hormone Replacement Responses." Osteopor	PTH 1-34 Treatment of Therapy: Biochemical, osis International, Vo	Osteoporosis with Added Kinetic and Histological 1. 1, 162-170, (1991).			
CR	Reeve, J. et al., "H Osteoporosis," Osteo	uman Parathyroid Pepti	de Treatment of Vertebral Vol. 1 Supplement, S199-203,			
CS	Treatment With Human	Parathyroid Hormone (al Bone in Osteoporotic Men by 1-34) and 1,25- Lineral Research, Vol. 1, No.			
CT	Neer, R.M. et al., "dihydroxyvitamin D t	." Osteoporosis, Vol.	Bone in Osteoporotic Men and 2, 829-835, (1987).			
cu	Reeve, J. et al., "P Alternating With Cal Spinal Osteoporosis, 17, 421-428, (1987).	Periodic Courses of Hum citriol Paradoxically " European journal of	an 1-34 Parathyroid Peptide Reduce Bone Remodelling in Clinical Investigation, Vol.			
cv	Reeve, J. et al., "T Peptide and Observat	reatment of Osteoporos tions on Effect of Sodi	is with Human Parathyroid um Fluoride, " BMJ, Vol. 301,			
udicte of CK	Demoster, D.W. et al Bone, " Endocrine Re	<u>l., "Anabolic Actions o</u> eviews, Vol. 14, No.6,	f Parathyroid Hormone on 690-709, (1993).			
uplicate of CK Rhi CX	Riggs B.L. et al.,	"Formation-Stimulating ican Journal of Medicin	Regimens Other Than Sodium ne, Vol. 95 supplement 5A, 5A-			
EXAMINER	Ruxing L	DATE CONSIDERED	7/29/2002			

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO	1448/70	modified)	Atty. Docket No. X-11965	Serial No 09/647,278			
INFORMATION DISCLOSURE CITATION		Applicant 09/64/,2/8					
IN AN APPLICATION		Janet M. Hock Filing Date Group					
							CY
RLI	 	Parathyroid Hormone	Plus Calcitriol,* Oste c	pporosis International, Vol.			
	CZ		2. et al., "Small Bone-Building Fragments of Parathyroid				
		Hormone: New Therape 386, (1995).	eutic Agents for Osteor	porosis," TiPS, Vol. 16, 382			
	CAA	Sone, T. et al., "A	Small Dose of Human Par	athyroid Hormone (1034) in Patients with Senile			
		Osteoporosis, " Miner	Electrolyte Metab, Vol	. 21, 232-235 (1995).			
	CAB	Reginster, J.Y. et a.	 "Parathyroid Hormor rosis: Back to the Fut 	ne in the Treatment of			
		International, Vol.	7 Supplement 3, S163-S1	.68 (1997).			
	CAC	Smith, S.Y. et al.,	"Efficacy of Recombinar	it Human Parathyroid Hormone lesus Monkeys," Journal of			
		Bone and Mineral Res	earch, Vol. 23, No.5, S	A456 Abstract, S633, (1998)			
	CAD	Finkelstein, J.S. et	al., "Increases in bor	ne density after nd PTH administration in wom			
		with endometriosis,"	Journal of Bone and Mi	ineral Research, Vol. 23,			
	CAE	Supplement No. 5, F4	59 Abstract, S518, (199 al., "Increases in Bor	ne Mineral Density after			
	52	Discontinuation of Da	aily Human Parathyroid	Hormone and Gonadotriopin-			
		Releasing Hormone And The Journal of Clinic	alog Administration in cal Endocrinology & Met	Women with Endometriosis, " cabolism, Vol. 84, No.4, 121			
		1219 (1999).		Iuman Parathyroid Hormone			
	CAF	Fragment (hPTH 1-34) Trabecular and Cortic Immunoassay, Proceed	in Osteoporosis: Opti cal Bone," <i>Monoclonal A</i> ings of the 3 rd Internat	mizing the Anabolic Effect Antibodies and Developments			
	CAG	Finkelstein, J.S. et	Parathyroid Hormone-(1	Estrogen Deficiency-Related 1-34)," JAMA, Vol. 280, No.			
	CAH	Finkelstein, J.S. et Bone Loss Induced by	al., "Parathyroid Horn	none for the Prevention of The New England Journal of (4).			
	CAI	Hodsman, A.B. et al. Prospects, "Chapter	, "Parathyroid Hormone:	The Clinical Experience a			
	CAJ	Rittmaster, R.S. et	al., "Treatment of Oste	eoporosis with Parathyroid			
J.		Hormone Followed by	Alendronate. Bone Marke -S517, Abstract F451, (er Results, " Bone, Vol. 23,			
<u> </u>	CAK	Lindsay, R. et al.,	"Randomised controlled	study of effect of			
divolentant		parathyroid hormone	on vertebral-bone mass on destrogen with oste	and fracture incidence amon eoporosis, " The Lancet, Vol.			
duplicate of		350, 550-555 (1997).					
	CAL						
	CAM						
	CAN						
	C20						
	CAO						
	CAP						

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO	1449	(modified)		Atty. X-119	Docket No. 65	Serial 09/647		REC	CEI	VED
INFORMATI IN AN APE	ON D	MAY 1 6 2001			cants M. Hock			MA'	Y 18;	2001
				Filin 9/26/	g Date 2000	Group 1654 (646	TECH CE	NTER 1) 600/290:
		A PADEMARK OF	U.S. PA	TENT	DOCUMENTS	}				Ì
Examiner Initial		Document Number	Date		Name	Class	Sub- class	Filing I: Approp	E	
RLi	AA	4,086,196	4/25/78	Trege	ear					
RLi	AB	4,698,328	10/6/87	Neer	et al.					
	AC									
	AD									
	<u> </u>	<u> </u>	FOREIGN	PATE	NT DOCUMENTS		· · · · · · · · · · · · · · · · · · ·			
		Document Number	Date		Country	Class	Sub- class	Transl	ation	
RLi	BA	98/14478	09.04.98	WO				yes_	no	
RL;	ВВ	99/12561	18.03.99	wo						•
RLi	BC	08073376	19.03.96	EP			<u> </u>			
	ОТН	ER DOCUMENTS (Incl	uding Aut	hor,	Title, Date, F	Pertinent Pa	iges, Etc	2.)	<u> </u>	
RLi	CA	Hormone Fra	agment (10 of Cortic	34), : cal Bo	ic Effects of LY333334, on F ne in Rabbits, 536-545 (1999)	Remodeling a ," Journal o	and Mech	anical		
	СВ	Lindsay, R. parathyroic postmenopau	et al., d hormone usal women 55 (1997).	"Rand on ve	omised control rtebral-bone mestrogen with	lled study on mass and fra osteoporosi	acture in is," The	ncidence Lancet,	Vol.	
	CC	Macgill, K.	et al.,	"Vasc	ular Effects of Circulation,	of PTHrP (1- " Placenta,	-34) and Vol. 18	РТН (1- , 587-59	34) in 2	
	CD	Lindsay, R. Fragment of Biochemical	Human Pa Response	arathy e in E	utaneous Admir roid Hormone- strogenized Os d Metabolism,	(1-34): Ki steoporotic	inetics a Patents	and ," <i>Journ</i>		
	CE	Lane, N. et Corticoster 8, 1627-163	oid-Induc	ced Os	roid Hormone T teoporosis," 3	Freatment Ca J. Clin. In	n Rever	se ol. 102,	No.	
	CF	Cosman F. o Osteoporosi Internation	et al., "] ls? A Rev nal, Vol.	Is Par view o 62, 4	athyroid Hormo f the Clinical 75-480 (1998).	l Evidence,'	" Calcif.	ied Tiss	ue	
	CG	Hesch, R.D. Metabolism Klinische	et al., in Osteor Vochen Sch	"Resu porosi hrift,	lts of a Stim s with (1-38)} Vol. 66, 976-	latory Them PTH and Dir -984 (1988)	phosphon	ate EHDP	', " 	
	СН	Cosman, F., of Parathyr 118, No. 5,	coid Hormo	one In	gen Protection fusion," Annal).	n against Bo ls of Intern	one Resonal Medi	rbing Ef cine, Vo	fects 1.	
EXAMINER		Ruisiang L.			DATE CONSIDER	7/29/200				
MPEP 609;	Draw	ial if citation c line through cita th next communica	tion if n	ot in	conformance a	tation is i nd not cons	n confor idered.	mance wi Include	th copy	

	,					
	Adjet A	Atty. Docket No. X-11965	Serial No 09/647,278			
INFORMATION DISCI IN AN APPLICATION		Applicant Janet M. Hock				
		Filing Date 9/26/2000	Group 1654 (646			
CI			mone (1034) and (1084)			
RLi 1		ical Strength and Thickness of Cortical Bone in Bone and Mineral Research, Vol. 3, No. 9, 1097-1101				
CJ	Parathyroid Hormone 1	1-34 Peptide in Ovaried	For 3 Months With Human ctomized Cynomolgus Monkeys 4, Supplement, 415S-420S			
CK ₁ ,	Bone, " Endocrine Revi	iews, Vol. 14, No. 6, 6				
CL	Parathyroid Hormone ((1-34) on Osteoporosis: .ng Three Dose Levels,"	ent Weekly Dose of Human A Randomized Double-Masked Osteoporosis International,			
СМ	Hesch, R.D. et al., " Therapy with Pulsatil	Increase of Vertebral e 1-38hPTH and Sequent porotic Patients," Calc	Density by Combination ial Addition of Calcitonin rified Tissue International,			
CN	Efficacy of Cyclical Hormone and Sequentia Women with Osteoporos	Parathyroid Hormone Ve				
со	Reeve, J. et al., "An on Trabecular Bone in	abolic Effect of Human	Parathyroid Hormone Fragment osis: A Multicentre Trial,"			
СР	Hesp, R. et al., "The Density and Calcium E Treated with Human Pa	Relationship between Balance in Patients wit	Changes in Femoral Bone Th Involutional Osteoporosis Thement (hPTH 1034)," Metabolic			
CÓ	Reeve, J. et al., "he Hormone Replacement T	TH 1-34 Treatment of C	Steoporosis with Added Kinetic and Histological			
CR	Reeve, J. et al., "Hu	man Parathyroid Peptic	le Treatment of Vertebral Vol. 1 Supplement, S199-203,			
CS	Slovik, D. M. et al.; Treatment With Human	Parathyroid Hormone (1	l Bone in Osteoporotic Men by -34) and 1,25- neral Research, Vol. 1, No.			
CT	Neer, R.M. et al., "T dihydroxyvitamin D to	The Use of Parathyroid Increase Trabecular E "Osteoporosis, Vol. 2	sone in Osteoporotic Men and			
С	Alternating With Calc	itriol Paradoxically R	n 1-34 Parathyroid Peptide deduce Bone Remodelling in Clinical Investigation, Vol.			
CV	Peptide and Observati 134-318 (1990).	ons on Effect of Sodiu	s with Human Parathyroid m Fluoride," BMJ, Vol. 301,			
Suplicate of CK	Dempster, D.W. et al.	, "Anabolic Actions of views, Vol. 14, No.6, 6	Parathyroid Hormone on 90-709, (1993).			
R~i cx			Regimens Other Than Sodium e, Vol. 95 supplement 5A, 5A-			
EXAMINER R	Puixiang L.	DATE CONSIDERED	7/29/2002			
*EXAMINER: Initial MPEP 609; Draw line	if citation considered	not in conformance and	ion is in conformance with not considered. Include copy			

of this form with next communication to the applicant.

FORM PTO 1448 (modif Serial No Atty. Docket No. X-11965 09/647,278 Applicant INFORMATION DISCLOSURE CITATION IN AN APPLICATION Janet M. Hock Filing Date Group 9/26/2000 -1654 1646 Neer, D.M. et al., "Treatment of Postmenopausal Osteoporosis with Daily CY Parathyroid Hormone Plus Calcitriol, " Osteoporosis International, Vol. 1 RLi Supplement, S204-205, (1993). Whitfield, J.F. et al., "Small Bone-Building Fragments of Parathyroid Hormone: New Therapeutic Agents for Osteoporosis, " TiPS, Vol. 16, 382-386, (1995). Sone, T. et al., "A Small Dose of Human Parathyroid Hormone (1034) CAA Increased Bone Mass in the Lumbar Vertebrae in Patients with Senile Osteoporosis, " Miner Electrolyte Metab, Vol. 21, 232-235 (1995). CAB Reginster, J.Y. et al., "Parathyroid Hormone in the Treatment of Involutional Osteoporosis: Back to the Future, " Osteoporosis International, Vol. 7 Supplement 3, S163-S168 (1997). Smith, S.Y. et al., "Efficacy of Recombinant Human Parathyroid Hormone CAC (1-84) (rhPTH, (1-84)) in Ovariectomized Rhesus Monkeys, " Journal of Bone and Mineral Research, Vol. 23, No.5, SA456 Abstract, S633, (1998) Finkelstein, J.S. et al., "Increases in bone density after CAD discontinuation of long-term GnRH analog and PTH administration in women with endometriosis, " Journal of Bone and Mineral Research, Vol. 23, Supplement No. 5, F459 Abstract, S518, (1998). CAE Finkelstein, J.S. et al., "Increases in Bone Mineral Density after Discontinuation of Daily Human Parathyroid Hormone and Gonadotriopin-Releasing Hormone Analog Administration in Women with Endometriosis, " The Journal of Clinical Endocrinology & Metabolism, Vol. 84, No.4, 1214-1219 (1999). CAF Reeve, J. et al., "The Therapeutic Use of Human Parathyroid Hormone Fragment (hPTH 1-34) in Osteoporosis: Optimizing the Anabolic Effect on Trabecular and Cortical Bone," Monoclonal Antibodies and Developments in Immunoassay, Proceedings of the 3rd International Conference on Radioimmunoassay 1981 held in Gardone Riviera, Italy, May 6-9, 1981. 239-246. Finkelstein, J.S. et. al., "Prevention of Estrogen Deficiency-Related CAG Bone Loss With Human Parathyroid Hormone-(1-34), " JAMA, Vol. 280, No. 12, 1067-1073 (1998). Finkelstein, J.S. et al., "Parathyroid Hormone for the Prevention of CAH Bone Loss Induced by Estrogen Deficiency, " The New England Journal of Medicine, Vol. 331, No. 24, 1618-1623, (1994). Hodsman, A.B. et al., "Parathyroid Hormone: The Clinical Experience and Prospects," Chapter 4, 83-108 (1998). CAT CAJ Rittmaster, R.S. et al., "Treatment of Osteoporosis with Parathyroid Hormone Followed by Alendronate. Bone Marker Results, " Bone, Vol. 23, (Suppl.), No.5, S516-S517, Abstract F451, (1998). CAK Lindsay, R. et al., "Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among duplicate of postmenopausal women on oestrogen with osteoporosis, " The Lancet, Vol. 350, 550-555 (1997). CAM CAN CAP EXAMINER DATE CONSIDERED Ruisiang L. 7/29/2002

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

	ISCLOSURE CITAT: TION Document Number	U.S. P2	X-11965 Applicants Janet M. Hock, et a Filing Date 9/26/2000 ATENT DOCUMENTS Name	Group 1654 Class	Sub- class	Filing Dat If Appropriat EIVEC 1 4 2002 WIER 1600/29)
AA AB AC AD AE AF AG AH			Filing Date 9/26/2000 ATENT DOCUMENTS	Group 1654 Class	Sub- class	Appropriat)
AB AC AD AE AF AG AH	Document Number		ATENT DOCUMENTS	Class	Sub- class	Appropriat)
AB AC AD AE AF AG AH	Document Number				REC	Appropriat)
AB AC AD AE AF AG AH	Document Number	Date	Name		REC	Appropriat)
AB AC AD AE AF AG AH			1		MAR	EIVEC 1 4 2002)
AC AD AE AF AG AH			4		MAR	1 4 2002	
AD AE AF AG AH			4		MAR	1 4 2002	
AE AF AG			1		MAR	1 4 2002	
AF AG AH			1				300
AG AH			1	1	ECH CEI	NTER 1600/25	300
АН			1				,
			3				
AI			<u> </u>		-		
	•		.]		J i	l	
ΑJ			:	-		·	
		FOREIGN	PATENT DOCUMENTS	L			
	Document Number		Country	Class	Sub-	Translatio	n
BD	08073376	19.03.96	JP		Class	yes no	<u> </u>
	·					х	
BE	08310965	26.11.96	JP			х	
BF							
THE	R DOCUMENTS (Incl	luding Aut	hor, Title, Date, Per	tinent Pag	ges, Etc)	
CAL_	J. Bone and	d Mineral	Research 8(9) (1993)	1097-1101	Human F	Parathyroid	-
e of	CI Hormone (1-	-34) and (1-84) Increase the Me	chanical	Strength	and	•-
<u> </u>				·			,
·	Ruisiang P		DATE CONSIDERED	7/29/202			
			whether or not citat	tion is in	conform	ranca with	_
niti	ial if citation co	CHOTACTER.		-1011 15 11	I COLLECTE	mance with Include cop	ı
		Purhang L	Rumang L nitial if citation considered.	Runang L. DATE CONSIDERED Date considered, whether or not citate	Runang L. DATE CONSIDERED Titial if citation considered, whether or not citation is in	Runang L. DATE CONSIDERED 7/29/2012	Runang L. DATE CONSIDERED 7/29/202